CVT And Gilead Look To Lock Out Astellas With Planned Merger
• By PharmAsia News
Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.